Beta Bionics, Inc. (BBNX)Healthcare | Medical Devices | Irvine, United States | NasdaqGM
16.87 USD
-0.82
(-4.635%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 17.14 +0.27 (1.600%) ⇧ (Oct. 14, 2026, 4:22 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 7:23 a.m. EDT
The investment case here is broken by a perfect storm of deteriorating fundamentals and overwhelming speculative fear. Fundamentally, the company is bleeding cash with negative operating margins of nearly 80%, negative free cash flow, and a trailing P/E that is mathematically impossible due to losses. While the business shows some top-line growth, the bottom line is collapsing, and the balance sheet is strained by debt relative to equity. The price action confirms this distress; the stock has been in a relentless freefall over the last two weeks, dropping from roughly $22.80 to $17.63, mirroring the broader trend of missed revenue estimates and slowing patient acquisition. This is not a temporary dip; it is a structural decline in market valuation driven by operational failures. Options activity provides the final nail in the coffin for any bullish thesis. The 'put wall' is immense, with traders aggressively buying insurance at strikes far below the current price, while call buyers are virtually absent. This asymmetry suggests that smart money expects further significant declines, not a recovery. With no dividend to provide income and a business model currently generating losses, there is no margin of safety. Avoid. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.184767 |
| AutoARIMA | 0.184768 |
| AutoTheta | 0.191623 |
| MSTL | 0.194383 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 4.92 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.126 |
| Excess Kurtosis | -0.21 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.54 |
| Revenue per Share | 2.689 |
| Market Cap | 910,072,640 |
| Forward P/E | -7.81 |
| Profit Margins | -61.31% |
| Website | https://www.betabionics.com |
As of Oct. 10, 2026, 7:23 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in deep out-of-the-money puts (strikes $5-$10) expiring in early 2027, while call activity is negligible and concentrated in the money. Implied volatility is significantly elevated for downside strikes compared to calls, indicating a market consensus of severe potential losses rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.16280168 |
| Address1 | 11 Hughes |
| All Time High | 32.71 |
| All Time Low | 8.8 |
| Ask | 17.63 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 966,830 |
| Average Daily Volume3 Month | 1,293,418 |
| Average Volume | 1,293,418 |
| Average Volume10Days | 966,830 |
| Bid | 10.42 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 5.699 |
| City | Irvine |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 16.87 |
| Current Ratio | 8.88 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 17.54 |
| Day Low | 16.72 |
| Debt To Equity | 2.54 |
| Display Name | Beta Bionics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,793,131,200 |
| Earnings Call Timestamp Start | 1,793,131,200 |
| Earnings Timestamp | 1,793,131,200 |
| Earnings Timestamp End | 1,793,131,200 |
| Earnings Timestamp Start | 1,793,131,200 |
| Ebitda | -80,799,000 |
| Ebitda Margins | -0.67891 |
| Enterprise To Ebitda | -7.697 |
| Enterprise To Revenue | 5.225 |
| Enterprise Value | 621,890,560 |
| Eps Current Year | -1.88 |
| Eps Forward | -2.16 |
| Eps Trailing Twelve Months | -1.64 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 18.8149 |
| Fifty Day Average Change | -1.9448986 |
| Fifty Day Average Change Percent | -0.10337013 |
| Fifty Two Week Change Percent | -16.280169 |
| Fifty Two Week High | 32.71 |
| Fifty Two Week High Change | -15.839998 |
| Fifty Two Week High Change Percent | -0.48425555 |
| Fifty Two Week Low | 8.8 |
| Fifty Two Week Low Change | 8.070001 |
| Fifty Two Week Low Change Percent | 0.91704553 |
| Fifty Two Week Range | 8.8 - 32.71 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,738,247,400,000 |
| Float Shares | 31,156,709 |
| Forward Eps | -2.16 |
| Forward P E | -7.8101854 |
| Free Cashflow | -40,294,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 420 |
| Fullday Change | -0.55000114 |
| Fullday Change Percent | -3.1091075 |
| Fullday Price | 17.14 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.58314997 |
| Gross Profits | 69,402,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00816 |
| Held Percent Institutions | 1.12866 |
| Implied Shares Outstanding | 53,946,211 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,025-01-30 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California. |
| Long Name | Beta Bionics, Inc. |
| Market | us_market |
| Market Cap | 910,072,640 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_365537151 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -72,973,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,197,066,422 |
| Number Of Analyst Opinions | 14 |
| Open | 17.35 |
| Operating Cashflow | -55,810,000 |
| Operating Margins | -0.79899 |
| Overall Risk | 8 |
| Phone | 949 427 7785 |
| Post Market Change | 0.26999855 |
| Post Market Change Percent | 1.6004655 |
| Post Market Price | 17.14 |
| Post Market Time | 1,792,009,361 |
| Previous Close | 17.69 |
| Price Eps Current Year | -8.973405 |
| Price Hint | 2 |
| Price To Book | 2.9601686 |
| Price To Sales Trailing12 Months | 7.646834 |
| Profit Margins | -0.61315 |
| Quick Ratio | 7.716 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | -0.8199997 |
| Regular Market Change Percent | -4.6353855 |
| Regular Market Day High | 17.54 |
| Regular Market Day Low | 16.72 |
| Regular Market Day Range | 16.72 - 17.54 |
| Regular Market Open | 17.35 |
| Regular Market Previous Close | 17.69 |
| Regular Market Price | 16.87 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 892,912 |
| Return On Assets | -0.16674 |
| Return On Equity | -0.26155 |
| Revenue Growth | 0.378 |
| Revenue Per Share | 2.689 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 53,946,211 |
| Shares Percent Shares Out | 0.1121 |
| Shares Short | 6,046,389 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 9,400,691 |
| Short Name | Beta Bionics, Inc. |
| Short Percent Of Float | 0.1125 |
| Short Ratio | 4.12 |
| Source Interval | 15 |
| State | CA |
| Symbol | BBNX |
| Target High Price | 30.4 |
| Target Low Price | 16.0 |
| Target Mean Price | 24.24286 |
| Target Median Price | 25.0 |
| Total Cash | 180,488,992 |
| Total Cash Per Share | 4.012 |
| Total Debt | 6,512,000 |
| Total Revenue | 119,013,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.64 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 15.3937 |
| Two Hundred Day Average Change | 1.4763012 |
| Two Hundred Day Average Change Percent | 0.09590295 |
| Type Disp | Equity |
| Volume | 892,912 |
| Website | https://www.betabionics.com |
| Zip | 92,618 |